• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.01% Nasdaq Up0.26%

    KaloBios Pharmaceuticals, Inc. (KBIO)

    26.63 Up 8.23(44.73%) Nov 25, 4:00PM EST
    |Pre-Market : 42.00 Up 15.37 (57.72%) 5:43AM EST - Nasdaq Real Time Price
    ProfileGet Profile for:
    KaloBios Pharmaceuticals, Inc.
    442 Littlefield Avenue
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-243-3100
    Website: http://www.kalobios.com

    Index Membership:N/A
    Full Time Employees:32

    Business Summary 

    KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. The company’s product candidates include KB004, which is in a Phase II clinical trial for the treatment of myelodysplastic syndrome and myelofibrosis; and KB003 that completed Phase II clinical trial to treat chronic myelomonocytic leukemia, an orphan oncology indication. KaloBios Pharmaceuticals, Inc. was founded in 2000 and is headquartered in South San Francisco, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on KaloBios Pharmaceuticals, Inc.

    Corporate Governance 
    KaloBios Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 2. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 2; Compensation: 2.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Martin Shkreli , 32
    Chairman of The Board and Chief Exec. Officer
    Dr. Geoffrey T. Yarranton Ph.D., 63
    Chief Scientific Officer
    Mr. Donald R. Joseph , 61
    Chief Legal Officer and Sec.
    Mr. Charles J. Democko , 60
    Sr. VP of Regulatory Affairs and Quality
    Dr. James W. Larrick Ph.D.,
    Chairman of Scientific Advisory Board and Consultant
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders